X0609 4 2026-06-02 false 0001667011 Arteris, Inc. AIP 0001184563 RAZA SAIYED ATIQ false C/O ARTERIS, INC. 900 E. HAMILTON AVE., SUITE 300 CAMPBELL CA 95008 true false false false true Common Stock 2026-06-02 4 A false 4703.00 0.00 A 25542.00 D Common Stock 2026-06-03 4 G false 20839.00 0.00 D 4703.00 D Common Stock 2026-06-03 4 G false 20839.00 0.00 A 160839.00 I By Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012 Common Stock 2026-06-03 4 S false 8332.00 37.6541 D 152507.00 I By Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012 Common Stock 2026-06-03 4 S false 800.00 38.4583 D 151707.00 I By Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012 Common Stock 2026-06-03 4 S false 11707.00 37.1294 D 140000.00 I By Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012 Includes 4,703 restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the annual meeting of the Issuer's stockholders following the grant date, subject to the reporting person continuing to provide services to Issuer's Board through such vesting date. The RSUs have no expiration date. This grant of restricted stock was made on June 2, 2026, based on the average trading price of Arteris, Inc. common stock for the period from April 21, 2026 through June 2, 2026, which was $31.89. The shares are transferred to Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the reporting person is the trustee. The shares are held by Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the Reporting Person serves as trustee. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on November 7, 2025. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.32 to $38.27 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $38.33 to $38.63 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.32 to $37.31 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Paul Alpern, as Attorney-in-Fact for S. Atiq Raza 2026-06-04